AR057106A2 - USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS - Google Patents
USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOSInfo
- Publication number
- AR057106A2 AR057106A2 ARP060103793A ARP060103793A AR057106A2 AR 057106 A2 AR057106 A2 AR 057106A2 AR P060103793 A ARP060103793 A AR P060103793A AR P060103793 A ARP060103793 A AR P060103793A AR 057106 A2 AR057106 A2 AR 057106A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen
- phenyl
- independently selected
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 25
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- -1 -CF3O- Chemical group 0.000 abstract 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un antagonista CCR5 de la reivindicacion 1 representado por la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la cual (a) Ra es R8a-fenilo, R8b-piridilo, R8b-tiofenilo o R8-naftilo; R1 es hidrogeno o alquilo C1- C6; R2 es heteroarilo de 6 miembros substituido con R9, R10 y R11; heteroarilo de 5 miembros substituído con R12 y R13; naftilo; fluorenilo; difenilmetilo, grupo de formulas (2); R3 es hidrogeno, alquilo C1-C6; alcoxi C1-C6-alquilo C1-C6, cicloalquilo C3-C10, cicloalquilo C3-C10-alquilo C1-C6, R8-fenilo, R8-fenilalquilo C1-C6, R8-naftilo, R8-naftilalquilo C1-C6, R8-heteroarilo o R8-heteroarilalquilo C1-C6; R4, R5, R7 y R13 están independientemente seleccionados del grupo que consiste en hidrogeno y alquilo C1-C6; R6 es hidrogeno, alquilo C1-C6 o alquenilo C2-C6; R8 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en hidrogeno, halogeno, alquilo C1-C6, alcoxi C1-C6, -CF3, CF3O-, CH3C(O)-, -CN, CH3SO2-, CF3SO2-, R14-fenilo, R14-bencilo, CH3C(=NOCH3), CH3C(=NOCH2CH3); formula (3) -NH2, -NHCOCF3, -NHCONH(alquilo C1-C6), -NHCO(C1-C6 alquilo), NHSO2(alquilo C1-C6), heteroarilo de 5 miembros y formula (4) donde X es -O-, -NH- o -N(CH3)-; R8a es de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en hidrogeno, halogeno, -CF3, -CF3O-, -CN, CF3SO2-, R14-fenilo, -NHCOCF3, heteroarilo de 5 miembros y formula (4) donde X es tal como se ha definido más arriba; R8a representa de 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en hidrogeno, halogeno, -CF3, CF3O-, CH3C(O)-, -CN, CF3SO2-, R14-bencilo, CH3C(=NOCH3), CH3C(=NOCH2CH3), formula (3), -NHCOCF3, heteroarilo de 5 miembros y formula (4) donde X es tal como se ha definido más arriba; R9 y R10 están independientemente seleccionados del grupo que consiste en alquilo C1-C6, halogeno, -NR17R18, -OH, -CF3, -OCH3, -O-acilo, -OCF3 y -Si(CH3)3; R11 es R9, hidrogeno, fenilo, - NO2, -CN, -CH2F, -CHF2, -CHO, -CH=NOR17, piridilo, N-oxido de piridilo, pirimidinilo, pirazinilo, -N(R17)CONR18R19, -NHCONH(cloro-alquilo C1-C6), -NHCONH(cicloalquilo C3-C10-alquilo C1-C6), -NHCOalquilo C1-C6, -NHCOCF3, -NHSO2N(alquilo C1-C6)2, _NHSO2alquilo C1-C6, -N(SO2CF3)2, -NHCO2alquilo C1-C6, cicloalquilo C3-C10, -SR20, -SOR20, -SO2R20, -SO2NH(alquilo C1-C6), -OSO2alquilo C1-C6, -OSO2CF3, hidroxialquilo C1-C6, -CONR17R18, -CON(CH2CH2-O-CH3)2, -OCONHalquilo C1-C6, -CO2R17, -Si(CH3)3 o -B(OC(CH3)2)2; R12 es alquilo C1-C6, -NH2 o R14-fenilo; R14 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en hidrogeno, alquilo C1-C6, -CF3, -CO2R17, -CN, alcoxiC1-C6 y halogeno; R15 y R16 están independientemente seleccionados del grupo que consiste en hidrogeno y alquilo C1-C6, o R15 y R16 conjuntamente son un grupo akquileno C2-C5 y con el carbono al cual están unidos forman un anillo espiro de 3 a 6 átomos de carbono; R17, R18 y R19 están independientemente seleccionados del grupo que consiste en H y alquilo C1-C6; y R20 es alquilo C1-C6 o fenilo; o (b)Ra es R8-fenilo, R8-piridilo o R8-tiofenilo; R2 es fluorenilo, difenilmetilo; grupo de formulas (2) heteroarilo y R1, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19 y R20 son tal como se ha definido en (a); y uno o más agentes antivirales seleccionados del grupo que consiste en inhibidores de retrotranscriptasa nucleosídica, inhibidores de retrotranscriptasa no nucleosídica, inhibidores de proteasa, hidroxiurea, ribavirina, IL-2, IL-12, pentafusida y Yissum N° 11607 para la preparacion de un medicamento para tratar el virus de inmunodeficiencia humana a un humano que necesite dicho tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30522699A | 1999-05-04 | 1999-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057106A2 true AR057106A2 (es) | 2007-11-14 |
Family
ID=23179892
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102096A AR023823A1 (es) | 1999-05-04 | 2000-05-02 | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. |
ARP060103793A AR057106A2 (es) | 1999-05-04 | 2006-08-30 | USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS |
ARP060103794A AR057107A2 (es) | 1999-05-04 | 2006-08-30 | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos |
ARP060103792A AR057786A2 (es) | 1999-05-04 | 2006-08-30 | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos |
ARP060104839A AR057873A2 (es) | 1999-05-04 | 2006-11-03 | Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102096A AR023823A1 (es) | 1999-05-04 | 2000-05-02 | Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos. |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103794A AR057107A2 (es) | 1999-05-04 | 2006-08-30 | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos |
ARP060103792A AR057786A2 (es) | 1999-05-04 | 2006-08-30 | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos |
ARP060104839A AR057873A2 (es) | 1999-05-04 | 2006-11-03 | Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1632479B1 (es) |
JP (2) | JP3722700B2 (es) |
KR (1) | KR100439358B1 (es) |
AR (5) | AR023823A1 (es) |
AT (2) | ATE299865T1 (es) |
AU (2) | AU780888B2 (es) |
BR (1) | BR0010304A (es) |
CA (1) | CA2371583C (es) |
CH (1) | CH1175401H9 (es) |
CL (1) | CL2008002737A1 (es) |
CO (1) | CO5170523A1 (es) |
CZ (1) | CZ20013940A3 (es) |
DE (2) | DE60021370C5 (es) |
DK (1) | DK1175401T3 (es) |
EG (1) | EG24136A (es) |
ES (1) | ES2244437T3 (es) |
HK (1) | HK1039930B (es) |
HU (1) | HUP0202867A3 (es) |
IL (1) | IL145741A0 (es) |
MY (1) | MY128367A (es) |
NO (1) | NO322045B1 (es) |
PE (1) | PE20010150A1 (es) |
PL (1) | PL203116B1 (es) |
RU (1) | RU2299206C9 (es) |
SA (2) | SA00210271B1 (es) |
SI (1) | SI1175401T1 (es) |
SK (2) | SK287418B6 (es) |
TR (1) | TR200103214T2 (es) |
TW (1) | TWI285200B (es) |
WO (1) | WO2000066558A1 (es) |
ZA (1) | ZA200108868B (es) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7825121B2 (en) | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
WO2002079194A1 (en) | 2001-03-29 | 2002-10-10 | Schering Corporation | Ccr5 antagonists useful for treating aids |
ATE418542T1 (de) | 2001-03-29 | 2009-01-15 | Schering Corp | Als ccr5-antagonisten verwendbare aryloxim- piperazine |
CN1596254A (zh) * | 2001-11-29 | 2005-03-16 | 先灵公司 | 含有增加量的旋转异构体的药物活性盐的组合物的制备方法 |
EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
JP4671091B2 (ja) * | 2002-03-18 | 2011-04-13 | 東レ・ファインケミカル株式会社 | 1−置換−2−メチルピペラジンの製造方法 |
EP2141153A3 (en) * | 2002-03-29 | 2010-05-26 | Schering Corporation | Stereoselective alkylation of chiral 2-methyl-4 protected piperazines |
CN100396676C (zh) * | 2002-03-29 | 2008-06-25 | 先灵公司 | 作为ccr5拮抗药的哌啶和哌嗪化合物的合成 |
WO2003090748A1 (fr) * | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Compay Limited. | Utilisation de composes a antagonisme anti-ccr |
JP2003335737A (ja) | 2002-05-21 | 2003-11-28 | Central Glass Co Ltd | 光学活性(r)−1−(4−トリフルオロメチルフェニル)エチルアミン |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
EP1570860A4 (en) * | 2002-12-13 | 2009-06-03 | Ono Pharmaceutical Co | ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR |
PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
JP4710606B2 (ja) | 2003-04-18 | 2011-06-29 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
EP1616862A4 (en) * | 2003-04-18 | 2008-07-16 | Ono Pharmaceutical Co | HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
KR20060009390A (ko) * | 2003-06-13 | 2006-01-31 | 쉐링 악티엔게젤샤프트 | Ccr-5 길항제로서의 퀴놀릴 아미드 유도체 |
GB0313661D0 (en) * | 2003-06-13 | 2003-07-16 | Avecia Ltd | Process |
EP1644366A1 (en) | 2003-06-30 | 2006-04-12 | Schering Corporation | Mch antagonists for the treatment of obesity |
JP4757802B2 (ja) | 2003-11-03 | 2011-08-24 | シェーリング コーポレイション | ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体 |
GB0329284D0 (en) * | 2003-12-18 | 2004-01-21 | Avecia Ltd | Process |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
ES2324224T3 (es) * | 2004-02-05 | 2009-08-03 | Schering Corporation | Derivados de piperidina que se pueden utilizar como antagonistas ccr3. |
WO2005075484A2 (en) * | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
EA011764B1 (ru) | 2004-03-05 | 2009-06-30 | Ниссан Кемикал Индастриз, Лтд. | Изоксазолинзамещённое производное бензамида и пестицид |
MXPA06011722A (es) | 2004-04-13 | 2007-01-25 | Incyte Corp | Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina. |
PT1761542E (pt) | 2004-06-09 | 2008-03-26 | Hoffmann La Roche | Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais |
GB0417804D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
TWI400232B (zh) | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
MX2007006695A (es) | 2004-12-03 | 2007-08-14 | Schering Corp | Piperazinas sustituidas como antagonistas de cb1. |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
EP1836190A2 (en) * | 2005-01-06 | 2007-09-26 | Schering Corporation | Preparation of pharmaceutical salts of piperazine compounds |
CN101189238A (zh) | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
WO2006088921A2 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
WO2006088840A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity |
WO2006088920A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
EP1856097B1 (en) * | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CN101163695A (zh) * | 2005-02-23 | 2008-04-16 | 先灵公司 | 用作趋化因子受体抑制剂的哌啶基哌嗪衍生物 |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
MX2007014928A (es) | 2005-06-02 | 2008-02-15 | Hoffmann La Roche | Derivados de piperidin-4-il-amida y su uso como antagonistas de subtipo 5 del receptor de somatostatina. |
US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
EP1940781A1 (en) | 2005-10-19 | 2008-07-09 | F.Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
ES2427989T3 (es) | 2005-10-28 | 2013-11-05 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
PL1961744T3 (pl) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
CA2629037A1 (en) * | 2005-11-30 | 2007-06-07 | Schering Corporation | Compositions comprising a combination of ccr5 and cxcr4 antagonists |
GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
NZ569814A (en) | 2006-01-18 | 2011-10-28 | Schering Corp | Cannibinoid receptor modulators |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
PL2322525T3 (pl) | 2006-04-21 | 2014-03-31 | Novartis Ag | Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub> |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
WO2008016006A1 (en) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
MX2009001198A (es) | 2006-08-16 | 2009-02-11 | Hoffmann La Roche | Inhibidores no nucleosidicos de la transcriptasa inversa. |
BRPI0717564A2 (pt) | 2006-09-29 | 2013-10-22 | Novartis Ag | Pirazolopirimidinas como inibidores de pi3k lipídeo cinase |
WO2008071587A2 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
RS51644B (en) | 2007-01-10 | 2011-10-31 | Irm Llc. | UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES |
JP5550352B2 (ja) | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
BRPI0809646A2 (pt) | 2007-03-29 | 2014-09-23 | Hoffmann La Roche | Compostod antivirais heterocíclicos |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
RU2010116821A (ru) * | 2007-10-01 | 2011-11-10 | Ф.Хоффманн-Ля Аг (Ch) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr |
PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
CA2716838C (en) * | 2008-02-29 | 2014-01-07 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
WO2009128947A1 (en) * | 2008-04-17 | 2009-10-22 | Concert Pharmaceuticals, Inc. | Piperazine derivatives |
AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
EP2379525B1 (en) | 2008-12-19 | 2015-07-29 | Boehringer Ingelheim International GmbH | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
ES2396023T3 (es) | 2009-01-29 | 2013-02-18 | Novartis Ag | Bencimidazoles sustituidos para el tratamiento de astrocitomas |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
JP5658272B2 (ja) * | 2009-12-17 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2の新規アンタゴニスト及びこれらの使用 |
ES2524829T3 (es) | 2009-12-17 | 2014-12-12 | Boehringer Ingelheim International Gmbh | Nuevos antagonistas del receptor CCR2 y usos de los mismos |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
WO2013105066A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Salts of an ip receptor agonist |
US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
EP2802581A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
EP2802585A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pah and related disorders |
US20140357641A1 (en) | 2012-01-13 | 2014-12-04 | Novartis Ag | IP receptor agonist heterocyclic compounds |
TW201335160A (zh) | 2012-01-13 | 2013-09-01 | Novartis Ag | Ip受體激動劑之雜環化合物 |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
JP2015536940A (ja) | 2012-10-29 | 2015-12-24 | シプラ・リミテッド | 抗ウイルス性ホスホネート類似体及びその製造方法 |
JP2016507582A (ja) | 2013-02-13 | 2016-03-10 | ノバルティス アーゲー | Ip受容体アゴニスト複素環式化合物 |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
CN106458979B (zh) | 2014-04-24 | 2020-03-27 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
ES2838573T3 (es) * | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
AU2016287584B2 (en) | 2015-07-02 | 2020-03-26 | Centrexion Therapeutics Corporation | (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
JOP20220044A1 (ar) | 2019-08-28 | 2023-01-30 | Novartis Ag | مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
AU8576098A (en) * | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
DE69919171T2 (de) * | 1998-06-30 | 2005-08-04 | Schering Corp. | Muskarin-rezeptor antagonisten |
-
2000
- 2000-05-01 BR BR0010304-7A patent/BR0010304A/pt not_active IP Right Cessation
- 2000-05-01 SI SI200030718T patent/SI1175401T1/xx unknown
- 2000-05-01 IL IL14574100A patent/IL145741A0/xx unknown
- 2000-05-01 AU AU45009/00A patent/AU780888B2/en not_active Expired
- 2000-05-01 KR KR10-2001-7013863A patent/KR100439358B1/ko not_active IP Right Cessation
- 2000-05-01 RU RU2001132632/04A patent/RU2299206C9/ru not_active IP Right Cessation
- 2000-05-01 CH CH926486.2T patent/CH1175401H9/de unknown
- 2000-05-01 SK SK5124-2007A patent/SK287418B6/sk not_active IP Right Cessation
- 2000-05-01 JP JP2000615389A patent/JP3722700B2/ja not_active Expired - Lifetime
- 2000-05-01 HU HU0202867A patent/HUP0202867A3/hu unknown
- 2000-05-01 PL PL351388A patent/PL203116B1/pl not_active IP Right Cessation
- 2000-05-01 CZ CZ20013940A patent/CZ20013940A3/cs unknown
- 2000-05-01 AT AT00926486T patent/ATE299865T1/de not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011632 patent/WO2000066558A1/en active Search and Examination
- 2000-05-01 DK DK00926486T patent/DK1175401T3/da active
- 2000-05-01 SK SK1569-2001A patent/SK286641B6/sk not_active IP Right Cessation
- 2000-05-01 DE DE60021370T patent/DE60021370C5/de not_active Expired - Lifetime
- 2000-05-01 ES ES00926486T patent/ES2244437T3/es not_active Expired - Lifetime
- 2000-05-01 CA CA002371583A patent/CA2371583C/en not_active Expired - Lifetime
- 2000-05-01 AT AT05010936T patent/ATE495154T1/de not_active IP Right Cessation
- 2000-05-01 EP EP05010936A patent/EP1632479B1/en not_active Expired - Lifetime
- 2000-05-01 EP EP00926486A patent/EP1175401B1/en not_active Expired - Lifetime
- 2000-05-01 TR TR2001/03214T patent/TR200103214T2/xx unknown
- 2000-05-01 DE DE60045528T patent/DE60045528D1/de not_active Expired - Lifetime
- 2000-05-02 EG EG20000563D patent/EG24136A/xx active
- 2000-05-02 AR ARP000102096A patent/AR023823A1/es active IP Right Grant
- 2000-05-02 PE PE2000000407A patent/PE20010150A1/es not_active Application Discontinuation
- 2000-05-02 CO CO00031259A patent/CO5170523A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001892A patent/MY128367A/en unknown
- 2000-05-02 TW TWPIPERAZINA patent/TWI285200B/zh active
- 2000-08-05 SA SA00210271A patent/SA00210271B1/ar unknown
- 2000-08-05 SA SA06270096A patent/SA06270096B1/ar unknown
-
2001
- 2001-10-26 ZA ZA200108868A patent/ZA200108868B/xx unknown
- 2001-11-02 NO NO20015366A patent/NO322045B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100824.0A patent/HK1039930B/zh not_active IP Right Cessation
-
2005
- 2005-05-31 AU AU2005202357A patent/AU2005202357B2/en not_active Expired
- 2005-08-16 JP JP2005236161A patent/JP2006052225A/ja not_active Withdrawn
-
2006
- 2006-08-30 AR ARP060103793A patent/AR057106A2/es unknown
- 2006-08-30 AR ARP060103794A patent/AR057107A2/es unknown
- 2006-08-30 AR ARP060103792A patent/AR057786A2/es unknown
- 2006-11-03 AR ARP060104839A patent/AR057873A2/es active IP Right Grant
-
2008
- 2008-09-15 CL CL2008002737A patent/CL2008002737A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057106A2 (es) | USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
EA199800404A1 (ru) | Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперазина | |
AR045931A1 (es) | Derivados de piperazina | |
AR030553A1 (es) | Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados | |
AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
AR127309A2 (es) | Derivados de piridazinona | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR005277A1 (es) | Derivados de piperidina 1-(piperidinil 1,2 disustituido)-4-sustituidos, proceso para su preparacion, composicion farmaceutica que los contienen,proceso para preparar dichas composiciones y uso de dichos derivados como medicamentos. | |
AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
AR041303A1 (es) | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4" | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
PE20060363A1 (es) | DERIVADOS DE TETRAAZABENZO[e]AZULENO Y SUS ANALOGOS | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
PE20000426A1 (es) | Uso de dihidropirimidinas como medicamento y nuevas sustancias | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
AR063790A1 (es) | Diaril ,dipiridinil y arilpiridinilderivados y usos de los mismos | |
AR065863A1 (es) | Derivados de imidazolidinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |